Tags

Type your tag names separated by a space and hit enter

Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.
Pediatr Blood Cancer. 2013 Oct; 60(10):1656-61.PB

Abstract

BACKGROUND

Vaccination against influenza is an important strategy in preventing severe infection among children with acute lymphoblastic leukemia (ALL). Successful vaccination depends on both vaccine and host-related factors. We conducted a study on factors predicting the immunogenicity of the monovalent pandemic H1N1 (pH1N1) influenza A vaccine in children with ALL.

METHODS

Children with ALL in our hospital were recruited and received two doses of the inactivated split-virion AS03-adjuvanted vaccine. The serological response was measured before each vaccine dose (Day 0 and 28) and 3 months after the second dose. Antibody titres were measured using a hemagglutination-inhibition assay. Seroconversion was defined as a ≥fourfold increase in antibody titre and a post-vaccination titre ≥1:40.

RESULTS

Pre and post-vaccination titres were available from 45 children with ALL after one dose of the vaccine and 39 children after two doses. The seroconversion rate was 11.1% after one dose and 25.6% after the second dose. Univariate analysis demonstrated a significantly higher (P = 0.01) seroconversion rate among children who received the adult dose (0.5 ml) of the vaccine and a trend towards increased seroconversion (P = 0.07) by multivariate analysis. Factors including age, gender, lymphocyte count, treatment phase and regimen did not significantly affect the seroconversion rate. Children who received the adult dose demonstrated a significantly greater magnitude of serological response after both one dose (P = 0.04) and two doses (P = 0.001).

CONCLUSIONS

These data suggest that the immunogenicity of the pH1N1 vaccine among children with ALL is improved by repeated and adult doses of the vaccine.

Authors+Show Affiliations

Department of Paediatric Infectious Diseases and Immunology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland. tronanleahy@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23682005

Citation

Leahy, T Ronan, et al. "Does Vaccine Dose Predict Response to the Monovalent Pandemic H1N1 Influenza a Vaccine in Children With Acute Lymphoblastic Leukemia? a Single-centre Study." Pediatric Blood & Cancer, vol. 60, no. 10, 2013, pp. 1656-61.
Leahy TR, Smith OP, Bacon CL, et al. Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study. Pediatr Blood Cancer. 2013;60(10):1656-61.
Leahy, T. R., Smith, O. P., Bacon, C. L., Storey, L., Lynam, P., Gavin, P. J., Butler, K. M., & O'Marcaigh, A. S. (2013). Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study. Pediatric Blood & Cancer, 60(10), 1656-61. https://doi.org/10.1002/pbc.24589
Leahy TR, et al. Does Vaccine Dose Predict Response to the Monovalent Pandemic H1N1 Influenza a Vaccine in Children With Acute Lymphoblastic Leukemia? a Single-centre Study. Pediatr Blood Cancer. 2013;60(10):1656-61. PubMed PMID: 23682005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study. AU - Leahy,T Ronan, AU - Smith,Owen P, AU - Bacon,Christopher L, AU - Storey,Lorna, AU - Lynam,Paul, AU - Gavin,Patrick J, AU - Butler,Karina M, AU - O'Marcaigh,Aengus S, Y1 - 2013/05/16/ PY - 2013/03/03/received PY - 2013/04/09/accepted PY - 2013/5/18/entrez PY - 2013/5/18/pubmed PY - 2013/11/2/medline KW - acute lymphoblastic leukemia KW - immunogenicity KW - influenza A KW - pandemic H1N1 KW - vaccine SP - 1656 EP - 61 JF - Pediatric blood & cancer JO - Pediatr Blood Cancer VL - 60 IS - 10 N2 - BACKGROUND: Vaccination against influenza is an important strategy in preventing severe infection among children with acute lymphoblastic leukemia (ALL). Successful vaccination depends on both vaccine and host-related factors. We conducted a study on factors predicting the immunogenicity of the monovalent pandemic H1N1 (pH1N1) influenza A vaccine in children with ALL. METHODS: Children with ALL in our hospital were recruited and received two doses of the inactivated split-virion AS03-adjuvanted vaccine. The serological response was measured before each vaccine dose (Day 0 and 28) and 3 months after the second dose. Antibody titres were measured using a hemagglutination-inhibition assay. Seroconversion was defined as a ≥fourfold increase in antibody titre and a post-vaccination titre ≥1:40. RESULTS: Pre and post-vaccination titres were available from 45 children with ALL after one dose of the vaccine and 39 children after two doses. The seroconversion rate was 11.1% after one dose and 25.6% after the second dose. Univariate analysis demonstrated a significantly higher (P = 0.01) seroconversion rate among children who received the adult dose (0.5 ml) of the vaccine and a trend towards increased seroconversion (P = 0.07) by multivariate analysis. Factors including age, gender, lymphocyte count, treatment phase and regimen did not significantly affect the seroconversion rate. Children who received the adult dose demonstrated a significantly greater magnitude of serological response after both one dose (P = 0.04) and two doses (P = 0.001). CONCLUSIONS: These data suggest that the immunogenicity of the pH1N1 vaccine among children with ALL is improved by repeated and adult doses of the vaccine. SN - 1545-5017 UR - https://www.unboundmedicine.com/medline/citation/23682005/Does_vaccine_dose_predict_response_to_the_monovalent_pandemic_H1N1_influenza_a_vaccine_in_children_with_acute_lymphoblastic_leukemia_A_single_centre_study_ L2 - https://doi.org/10.1002/pbc.24589 DB - PRIME DP - Unbound Medicine ER -